-
Kyiv in mourning after 24 killed as Ukraine, Russia swap POWs
-
Beckham becomes first British billionaire sportsman
-
Aussie star, Danish clubbing ode through to Eurovision final
-
German Oscar winner Huller feels war guilt 'every day'
-
Thai lawmakers vote to revive clean air bill
-
Bayern warn that Canada's Davies struggling to be fit for World Cup
-
Long-serving Coleman to end Everton career at end of season
-
Energy-hungry German industries in decline since Ukraine war: data
-
Gordon may have made last Newcastle appearance: Howe
-
Denmark's Queen Margrethe has angioplasty in hospital: palace
-
Civilians caught in war of drones in eastern DR Congo
-
French city reels from teen killing in drug-linked shooting
-
NZ passenger from hantavirus cruise quarantines in Taiwan
-
Sci-fi or battlefield reality? Ukraine's bet on drone swarms
-
Russia, Ukraine swap 205 prisoners of war each
-
Southeast Asia's largest dinosaur identified in Thailand
-
Rapprochement, debates, dissidents: US presidential visits to China
-
Indian magnate Adani agrees multi-million-dollar penalty in US court case
-
Drones to fight school shooters? One US company says yes
-
Mines 'draining Turkey's water sources', environmentalists warn
-
Zimbabwe tobacco hits new highs under smallholder contracts
-
War imperils rare vultures' yearly odyssey to the Balkans
-
Russian border city shrugs off Baltic fears of attack
-
Bitter church row divides Armenia ahead of elections
-
India hikes fuel prices as Middle East war strains supplies
-
Injured Mitoma fails to make Japan's World Cup squad
-
Malaysia PM says not opposed to fugitive financier's bid for pardon
-
Passenger from hantavirus cruise quarantines on remote Pitcairn Island
-
Duplantis kicks off Diamond League season in China
-
Arsenal scent Premier League glory
-
Russia pummels Kyiv, killing at least 24 and denting peace hopes
-
Rare South-North Korea football match sells out in 12 hours
-
Six hantavirus cruise passengers land in Australia
-
Markets wait on Trump-Xi summit, Seoul hits record
-
Solomon Islands elects opposition leader Matthew Wale as PM
-
Football: 2026 World Cup stadium guide
-
Hearts must run Celtic gauntlet to claim historic Scottish title
-
All at stake for Bundesliga relegation battlers on final day
-
Trump traded hundreds of millions in US securities in 2026
-
Can World Cup fuel North America's soccer boom?
-
Bulgaria's pro-Russians seek place after Radev win
-
Canada's Cohere embraces 'low drama' amid AI giant tumult
-
Sci-fi or battlefield reality? Ukraine's bet on swarm drones
-
India seeks trade, energy stability on UAE-Europe tour
-
Five things to look out for in La Liga this weekend
-
Man City battle 'fatigue' ahead of FA Cup final clash with troubled Chelsea
-
Egypt farmers hit by Iran war price surge
-
Harry Styles: from teen heart-throb to music icon
-
CIA director visits Cuba as communist island runs out of oil
-
Seahawks face Patriots in Super Bowl rematch to open NFL season
Trump administration does about face on autism treatment
The Trump administration did an about-face Tuesday on an autism treatment it had promoted with great fanfare.
It had said back in September it would approve use of a drug called leucovorin -- synthetic vitamin B9 -- to treat the disorder.
But on Tuesday the Food and Drug Administration backed off, citing insufficient evidence that it works for the condition.
The initial announcement came from Health Secretary Robert F. Kennedy Jr, who for decades has spread debunked claims that vaccines cause autism.
Kennedy touted leucovorin, usually used to alleviate chemotherapy side effects, as an "exciting therapy" that could help children with autism, a disorder whose symptoms vary widely across a spectrum.
"This gives hope to the many parents with autistic children that it may be possible to improve their lives," President Donald Trump said in September at a press conference.
At the event he gave sweeping, unsubstantiated advice on autism, such as insisting that pregnant women should "tough it out" and avoid Tylenol over an unproven link to autism -- statements slammed by scientists.
Studies on a small number of patients have suggested that taking leucovorin can help ease some communication or personal-relations problems linked to autism, but experts say this issue needs more study.
On Tuesday the FDA said it was in fact approving use of leucovorin for a rare condition called cerebral folate deficiency but not for autism.
The Trump administration's touting of it for autism ran the risk of raising false hopes, dozens of autism specialists said at the time in a joint letter.
"We don't have sufficient data to say that we could establish efficacy for autism more broadly," an FDA official told NBC News.
"It'll be up to patients to talk with their physicians to see if that might be right for them," said the official, whose name was not given.
O.M.Souza--AMWN